
NASH-focused Akero Therapeutics extends its runway by another year with Pfizer's help
Two years ago, Akero Therapeutics laid out what one analyst called the “best-in-class NASH data so far” in a field littered with trial failures and ambiguous readouts. Following those interim Phase II results, Akero embarked on a larger Phase II trial that is supposed to report out later this year.
But things weren’t looking up for the San Francisco-based biotech when it revealed in its Q1 earnings report that it had just a year and a half of cash left — not enough to push its drug into pivotal Phase III clinical trials that would support an FDA approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.